What has SMC said?
The Scottish Medicines Consortium (SMC) has accepted lisocabtagene maraleucel for the treatment of adult patients with diffuse large B-Cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). It is used when the cancer has come back less than 12 months after a type of treatment called chemoimmunotherapy or has not responded to this treatment.
You can find more detailed information about the SMC assessment of lisocabtagene maraleucel by looking at the SMC Detailed Advice Document (SMC2909).
What does SMC’s decision mean for patients?
Lisocabtagene maraleucel for use as described above is available for prescribing on the NHS in Scotland. Your healthcare professional can discuss with you if it is the right treatment for you.
You can find more information about making decisions about your treatment here:
More about SMC’s decision
SMC’s decision takes into account a confidential discount offered by the pharmaceutical company.
How does SMC make its decision?
SMC carefully considers every new medicine to make sure it benefits patients and is likely to be a good use of NHS resources.
To do this SMC studies the following:
- Evidence from the company about how well the medicine works compared with current treatments available in Scotland, in relation to how much they will cost to buy and use to treat patients.
- Information from patient groups about the potential impact of the medicine on patients and carers.
- Advice from healthcare professionals about any benefits of the new medicine compared to current treatment, along with how the new medicine is likely to be used.
When SMC assesses a medicine it takes account of the needs of all patients in NHSScotland, not only those who may be treated with the medicine.
You can find out more about how SMC decides here: https://www.scottishmedicines.org.uk/how-we-decide/
More information and support
The organisation below can provide more information and support for people with lymphoma and their families. SMC is not responsible for the content of any information provided by external organisations.
Lymphoma Action
https://lymphoma-action.org.uk 0808 808 5555
You can find out more about lisocabtagene maraleucel (brand name: Breyanzi®) in the Patient Information Leaflet (PIL) by searching for the medicine name on the Medicines and Healthcare products Regulatory Agency (MHRA) website.
https://products.mhra.gov.uk/